Tampa General Hospital Adopts Microbot’s LIBERTY Robotic System, First in Florida

Event summary

  • Tampa General Hospital is the first in Florida to adopt Microbot Medical’s LIBERTY Endovascular Robotic System, following FDA 510(k) clearance.
  • The system aims to reduce radiation exposure and physical strain in peripheral endovascular procedures.
  • Microbot plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026.
  • Tampa General is a nationally ranked academic medical center serving 15 counties with over 6 million people.

The big picture

Tampa General’s adoption of LIBERTY signals growing institutional readiness for robotic solutions in endovascular procedures. Microbot’s strategic push aligns with broader industry trends toward minimizing physician strain and radiation exposure. The limited market release and planned full launch at SIR suggest a deliberate, phased commercialization strategy.

What we're watching

Adoption Pace
How quickly other Florida hospitals will adopt LIBERTY following Tampa General’s lead.
Commercial Scaling
Whether Microbot can sustain momentum ahead of the full market release in April 2026.
Market Penetration
The pace at which LIBERTY can capture share in the $2.5M annual peripheral endovascular procedure market.